<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
<channel rdf:about="http://hdl.handle.net/10379/1241">
<title>Network of Excellence for Functional Biomaterials (Conference Papers)</title>
<link>http://hdl.handle.net/10379/1241</link>
<description/>
<items>
<rdf:Seq>
<rdf:li rdf:resource="http://hdl.handle.net/10379/4226"/>
</rdf:Seq>
</items>
<dc:date>2017-10-29T23:02:47Z</dc:date>
</channel>
<item rdf:about="http://hdl.handle.net/10379/4226">
<title>Neurotrophic Factor-Expressing Mesenchymal Stem Cells Survive Transplantation into the Contused Spinal Cord Without Differentiating into Neural Cells</title>
<link>http://hdl.handle.net/10379/4226</link>
<description>Neurotrophic Factor-Expressing Mesenchymal Stem Cells Survive Transplantation into the Contused Spinal Cord Without Differentiating into Neural Cells
Rooney, Gemma E.; McMahon, Siobhan; Ritter, Thomas; Garcia, Yolanda; Moran, Cathal; Madigan, Nicholas N.
The aim of this study was to assess the feasibility of transplanting mesenchymal stem cells (MSCs), genetically modified to express glial-derived neurotrophic factor (GDNF), to the contused rat spinal cord, and to subsequently assess their neural differentiation potential. MSCs expressing green fluorescent protein were transduced with a retroviral vector to express the neurotrophin GDNF. The transduction protocol was optimized by using green fluorescent protein-expressing retroviral constructs; approximately 90% of MSCs were transduced successfully after G418 selection. GDNF-transduced MSCs expressed the transgene and secreted growth factor into the media (similar to 12 ng/500,000 cells secreted into the supernatant 2 weeks after transduction). Injuries were established using an impactor device, which applied a given, reproducible force to the exposed spinal cord. GDNF-expressing MSCs were transplanted rostral and caudal to the site of injury. Spinal cord sections were analyzed 2 and 6 weeks after transplantation. We demonstrate that GDNF-transduced MSCs engraft, survive, and express the therapeutic gene up to 6 weeks posttransplantation, while maintaining an undifferentiated phenotype. In conclusion, transplanted MSCs have limited capacity for the replacement of neural cells lost as a result of a spinal cord trauma. However, they provide excellent opportunities for local delivery of neurotrophic factors into the injured tissue. This study underlines the therapeutic benefits associated with cell transplantation and provides a good example of the use of MSCs for gene delivery.
Journal article
</description>
<dc:date>2009-10-01T00:00:00Z</dc:date>
</item>
</rdf:RDF>
